Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | IDH1 R132H IDH1 D279N |
| Therapy | Ivosidenib |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH1 R132H IDH1 D279N | acute myeloid leukemia | predicted - resistant | Ivosidenib | Preclinical - Cell culture | Actionable | In a preclinical study, Tibsovo (ivosidenib) modestly suppressed (R)-2-hydroxyglutarate (R-2HG) production in an acute myeloid leukemia cell line expressing IDH1 R132H and D279N but did not inhibit cytokine-independent growth in culture (PMID: 36056177). | 36056177 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36056177) | Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma. | Full reference... |